CORALLINI, Federica
 Distribuzione geografica
Continente #
NA - Nord America 3.471
AS - Asia 615
EU - Europa 595
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.686
Nazione #
US - Stati Uniti d'America 3.463
CN - Cina 353
UA - Ucraina 185
SG - Singapore 136
TR - Turchia 110
IT - Italia 105
GB - Regno Unito 102
DE - Germania 100
FI - Finlandia 45
SE - Svezia 32
CZ - Repubblica Ceca 9
CA - Canada 8
FR - Francia 6
BE - Belgio 5
IR - Iran 5
AU - Australia 4
ID - Indonesia 3
LT - Lituania 3
HK - Hong Kong 2
IN - India 2
EU - Europa 1
HR - Croazia 1
IL - Israele 1
IQ - Iraq 1
KR - Corea 1
MY - Malesia 1
NL - Olanda 1
RU - Federazione Russa 1
Totale 4.686
Città #
Fairfield 505
Woodbridge 470
Houston 264
Ashburn 224
Ann Arbor 221
Seattle 221
Chandler 211
Jacksonville 209
Cambridge 183
Wilmington 166
Santa Clara 141
Singapore 112
Beijing 68
Nanjing 68
Izmir 66
Princeton 47
New York 45
San Diego 35
Boardman 34
Milan 31
Shanghai 26
Shenyang 25
Nanchang 23
Los Angeles 21
Ferrara 20
Changsha 14
Falls Church 13
Jinan 13
San Mateo 13
Auburn Hills 11
Hebei 11
Mountain View 11
Zhengzhou 11
Tianjin 10
Dearborn 9
Munich 8
Bremen 7
Brno 7
Philadelphia 7
Haikou 6
London 6
Redwood City 6
Brussels 5
Kunming 5
Norwalk 5
Ottawa 5
Tappahannock 5
Ardabil 4
Frankfurt am Main 4
Leawood 4
Augusta 3
Changchun 3
Des Moines 3
Hangzhou 3
Helsinki 3
Jiaxing 3
Padova 3
Taizhou 3
Toronto 3
Verona 3
Walnut 3
Castelnuovo Scrivia 2
Chongqing 2
Guangzhou 2
Hong Kong 2
Hounslow 2
Jakarta 2
Kilburn 2
Ningbo 2
Prescot 2
Redmond 2
Rome 2
San Francisco 2
Taiyuan 2
Washington 2
Acton 1
Addison 1
Amsterdam 1
Atlanta 1
Bologna 1
Cascina 1
Clearwater 1
Deyang 1
Edinburgh 1
Forest City 1
Harbin 1
Indiana 1
Kuantan 1
Lecce 1
Logan 1
Monmouth Junction 1
New Bedfont 1
Olomouc 1
Orange 1
Prague 1
Pune 1
Salerno 1
Sandston 1
Shaoxing 1
Shenzhen 1
Totale 3.722
Nome #
Antiangiogenic activity of the MDM2 antagonist nutlin-3 139
Potential role of PKC inhibitors in the treatment of hematological malignancies 136
Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-hodgkin's lymphoma xenografts 135
In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody. 134
Nutlin-3 upregulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feed-back anti-apoptotic mechanism 132
Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes 129
TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release 129
Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults 128
TRAIL and osteoprotegerin: a role in endothelial physiopathology? 121
Elevated levels of TRAIL in systemic lupus erythematosus are associated to the presence of anti-SSA/SSB antibodies. 120
TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells 120
Conjunctival sac fluid contains elevated levels of soluble TRAIL: implications for the anti-tumoral surveillance of the anterior surface of the eye 120
Is there any role for tumour necrosis factor related apoptosis inducing ligand–osteoprotegerin (TRAIL–OPG) interaction in rheumatoid arthritis? 119
Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells 119
Circulating levels of frizzled-related protein (FRZB) are increased in patients with early rheumatoid arthritis and decrease in response to disease-modifying antirheumatic drugs. 119
Anti-leukemic activity of Dasatinib in both p53(wild-type) and p53 (mutated) B malignant cells. 119
Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts 117
Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells 113
Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. 112
The tumour necrosis factor-related apoptosis inducing ligand-osteoprotegerin system in limited systemic sclerosis: a new disease marker? 112
Mesenchymal stem cells-derived vascular smooth muscle cells release abundant levels of osteoprotegerin 108
Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells 106
Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction 106
TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors 105
Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice 103
null 102
TRAIL, caspases and maturation of normal and leukemic myeloid precursors 102
TNFRSF11B (tumor necrosis factor receptor superfamily, member 11b) 98
null 97
Metalloproteinase 2 cleaves in vitro recombinant TRAIL: Potential implications for the decreased serum levels of TRAIL after acute myocardial infarction 94
null 94
Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells 92
The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis 91
null 90
null 89
null 88
null 86
null 78
null 74
null 65
TNF-α modulates the migratory response of mesenchymal stem cells to TRAIL 64
Ruolo di trail nella patogenesi del danno neuronale indotto dalla proteina Tat di HIV-1 47
Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand 40
Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells 39
An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction 32
An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction 29
Human Full-Length Osteoprotegerin Induces the Proliferation of Rodent Vascular Smooth Muscle Cells both in vitro and in vivo 27
Baseline serum concentrations of TRAIL in early rheumatoid arthritis: Relationship with response to disease-modifying antirheumatic drugs 27
Insulin down-regulates TRAIL expression in vascular smooth muscle cells both in vivo and in vitro 24
Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo 21
Selective induction of TP53I3/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3 18
The potential role of Nutlins in the treatment of B-chronic lymphocytic leukemia (B-CLL) 11
Totale 4.720
Categoria #
all - tutte 20.318
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.318


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020518 0 0 0 0 0 0 107 118 89 125 58 21
2020/2021566 49 55 19 90 20 56 15 73 16 68 75 30
2021/2022522 15 57 56 11 15 26 35 25 14 29 66 173
2022/2023457 40 23 17 49 80 78 25 40 47 7 28 23
2023/2024197 16 26 3 5 11 51 9 13 1 3 3 56
2024/2025386 21 32 66 50 144 72 1 0 0 0 0 0
Totale 4.720